Non-small cell lung cancer
Conditions
Interventions
pembrolizumab 200 mg every 3 weeks
Sponsors
Department of Respiratory Internal medicine, Hiroshima Univestity Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) ECOG PS 0 or 1 2) Non-small cell lung cancer 3) Stage IIIB or IV or recurrence 4) PD-L1 tumor proportion score of 50% or greater 5) No sensitizing EGFR mutations or ALK translocations 6) Chemotherapy naive 7) Provided written informed consent 8) With adequate organ function
Exclusion criteria
Exclusion criteria: 1) Pleural effusion, ascites or pericardialeffusion requiring drainage 2) Other cancers 3) Symptomatic brain metastasis and meningitis 4) With severe complication 5) Interstitial pneumonia on CT 6) Severe drug allergy 7) Active autoimmune disease that has required systemic treatment 8) Dementia 9) Other conditions not suitable for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate Disease Control Rate Overall survival Safety QOL | — |
Countries
Japan
Contacts
Public ContactTakeshi Masuda
Hiroshima University Department of Respiratory Internal medicine, Hiroshima Univestity Hospital
Outcome results
None listed